Item 8.01 Other Events.
Sangamo Therapeutics, Inc. is filing this report for the purpose of filing a
copy of the slides containing updated follow-up data from the Phase 1/2 Alta
study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy
for patients with severe hemophilia A, that were presented on December 7, 2020
at the 62nd American Society of Hematology (ASH) Annual Meeting (the "Data
Presentation"). A copy of the Data Presentation is attached as Exhibit 99.1 to
this report and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
No. Description
99.1 2020 American Society of Hematology (ASH) Annual Meeting Data
Presentation
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses